Division of Merck & Co. Inc.
Latest From Schering-Plough Corp.
While leading large pharma with seven out-licensing or divestiture deals apiece during 2018, AstraZeneca and Novartis each slowed their pace somewhat. But several peer companies followed suit, as there were 31 such deals among the 20 largest biopharma firms last year.
Settlement reflects existing landscape in which companies are avoiding no-authorized generic commitments, and may harbinger FTC's shift to other issues.
Reps. Welch and Rooney urge FTC and DOJ to condition their approval of the merger on inclusion of a pricing provision.
Antibody developer Harbour Biomed signs its first deal for rights outside China in cancer pact with Kelun. Portage buys SalvaRx to increase its immuno-oncology capabilities, while Paragon spinout Emalex will take over Psyadon’s pediatric Tourette syndrome program.
- OTC, Consumer
- Therapeutic Areas
- Immune Disorders
- Infectious & Viral Diseases
- Musculoskeletal & Connective Tissue Disorders
- Respiratory, Pulmonary
- North America
- Parent & Subsidiaries
Merck & Co. Inc.
- Canji Inc.
- DNAX Research Institute
- Essex Chemie AG
- Integrated Therapeutics Group Inc.
- Key Pharmaceuticals Inc.
- NeoGenesis Pharmaceuticals Inc.
- Organon NV
- Schering Canada
- Schering Corp.
- Schering Laboratories
- Schering-Plough (Brinny) Co.
- Schering-Plough Healthcare Products Inc.
- Schering-Plough Ltd.
- Schering-Plough Pharmaceuticals
- Schering-Plough Research Institute
- Scholl International
- Scholl US Division
- Shanghai Schering-Plough Pharmaceutical Co. Ltd.
- Warrick Pharmaceuticals
- Schering-Plough Corp.
- Senior Management
Fred Hassan, Chmn. & CEO
Robert Bertolini, EVP, CFO
David A Piacquad, SVP, Bus. Dev.
- Contact Info
Phone: (908) 298-4000
2000 Galloping Hill Rd.
Kenilworth, NJ 07033-0530
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.